Citations

Clear

422 citation(s) found for "Stål, Per".

Supernatants from stored platelet concentrates modulate the inflammatory response in platelet-depleted blood ex vivo
Andersson, Linnéa , Sjöström, Dick J. , Tynngård, Nahreen , Mohlin, Camilla , Quach, Huy Quang , Tjernberg, Ivar , Ramström, Sofia , Mollnes, Tom Eirik , Nilsson, Per H.

Mayo Clinic

Frontiers in Immunology | October 5, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1928875 | PMID 42898267 Get It

Introduction Platelets contain a wide range of bioactive mediators, many of which accumulate during storage of platelet concentrates and have immunomodulatory properties. Our objective was to investigate how mediators derived from stored platelet concentrates modulate the acute inflammatory response using an ex vivo model. Methods Platelet-depleted whole blood from healthy donors (n=8) was supplemented with pooled platelet concentrate supernatants generated from six platelet concentrates sampled on storage days 1, 3, 5, and 7, and incubated with or without heat-inactivated Escherichia coli for four hours at 37 °C. Inflammatory responses were assessed by measuring complement activation, platelet-derived mediators, and cytokines. Results In the absence of E. coli , addition of platelet concentrate supernatants increased the levels of 24 of 32 measured inflammatory mediators. In contrast, under E. coli -stimulated conditions, the supernatants increased 10 markers and attenuated 14 markers, including the key pro-inflammatory cytokines IL-1β, IL-6, and TNF. The attenuation of these cytokines ranged from 25-43%, whereas several other mediators were unchanged or increased. The majority of biomarkers showed limited differences across the investigated storage time points. Conclusions Our findings demonstrate that soluble factors released from platelet concentrates can modulate inflammatory responses in platelet-depleted blood in an ex vivo setting, with context-dependent, bidirectional, and selective immunomodulatory effects.
Diagnostic Accuracy and Alignment With Human Reader Responses Across Five Large Language Models on Complex Clinical Case Challenges
Bellocco, Rino , Soraci, Luca, Lo Cicero, Lorenzo , Silipigni, Salvatore , Lanfranchi, Giuseppe , Sciascia, Savino , Cheungpasitporn, Wisit, Santoro, Domenico , Gembillo, Guido , Gembillo, Guido , Soraci, Luca , Cheungpasitporn, Wisit , Corsonello, Andrea

Mayo Clinic

Epidemiology, Biostatistics, and Public Health | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54103/2282-0930/32167 Get It

Introduction: Large language models (LLMs) match or exceed physician accuracy on benchmark diagnostic tasks. Whether higher accuracy reflects human-like diagnostic behavior, which bears on how safely clinicians can supervise these systems, is rarely assessed. Objectives: To determine whether diagnostic accuracy and alignment with human reader responses move together across widely accessible LLMs under default, point-of-care conditions. Methods: This cross-sectional evaluation submitted the 29 most recent New England Journal of Medicine (NEJM) case challenges to 5 publicly accessible LLMs (GPT-5, Claude, Google Gemini, DeepSeek, and Grok) through each model’s web interface (November 5-8, 2025) at default settings, one query per case, no system prompt. Each case offered a clinical vignette and 6 candidate diagnoses; published human reader response distributions (4386-17 714 per case; median, 7732) were the comparator. Diagnostic accuracy against the published gold-standard diagnosis, compared with the human reader majority by the exact McNemar test; agreement by Cohen κ; alignment by a human-error similarity index (the share of model errors on cases the reader majority also missed) and by the Jensen-Shannon divergence (JSD) between each model’s response and the reader distribution; and ordinary least squares regression of per-case JSD on normalized reader-disagreement entropy. Results: Reader majority accuracy was 48.3% (95% CI, 31.4-65.6). All 5 reached or exceeded this value, from 51.7% for DeepSeek (95% CI, 34.4-68.6) to 82.8% for Grok (95% CI, 65.5-92.4); Grok (P = .02), GPT-5 (P = .004), and Gemini (P = .04) significantly exceeded the reader majority, whereas Claude and DeepSeek did not. Grok, the most accurate model, showed the weakest alignment (similarity index, 0.40; mean JSD, 0.50 bits), with 3 of 5 errors on cases readers answered correctly. GPT-5 showed the strongest alignment (index, 1.000), failing only on cases that also challenged readers. For 4 of 5 models, divergence rose with reader-disagreement entropy; DeepSeek was the exception. Conclusions and Relevance: In this evaluation, diagnostic accuracy and alignment with human reader responses diverged across LLMs. Because a model can outperform clinicians in aggregate yet fail where oversight is least likely to detect it, evaluation of clinical AI should weigh error structure alongside accuracy.
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Prinzi, Federica Lo , Rimini, Margherita , Ikeda, Masafumi, Antonuzzo, Lorenzo, Kim, Jin Won, Pressiani, Tiziana, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Tamberi, Stefano, Couto, Nuno, Chon, Hong Jae, Martirena, A. , Lamarca, Angela, Perkhofer, Lukas , Kim, Il Hwan, Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Satake, Tomoyuki, Bekaii‐Saab, Tanios, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Prete, Alessandra Anna, Bozzarelli, Silvia, Persano, Mara , Masi, Gianluca, Balsano, Rita , Lonardi, Sara, Salani, Francesca, Camera, Silvia, Vogel, Arndt, Rimassa, Lorenza, Rimassa, Lorenza , Vivaldi, Caterina , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Lo Prinzi, Federica , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Kim, Jin Won , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno, Chon, Hong Jae , Lamarca, Angela , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan, Formica, Vincenzo , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Warmington, Emily, Satake, Tomoyuki , Bekaii‐Saab, Tanios , Giordano, Guido , Ferrara, Michele , Kang, Minsu, Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Vogel, Arndt , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70699 | PMID 42581755 Get It

ABSTRACT Many real‐world patients with advanced biliary tract cancer (BTC) are excluded by TOPAZ‐1 criteria; this study assessed cisplatin and gemcitabine plus durvalumab (CGD) efficacy and safety in these patients. Data from 1358 patients with advanced BTC treated with first‐line CGD across 55 international centers were retrospectively analyzed. Patients were classified as TOPAZ‐1‐in (meeting all inclusion criteria) or TOPAZ‐1‐out (meeting ≥ 1 exclusion criterion). Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Furthermore, OS and PFS of the TOPAZ‐1‐out cohort were compared with reconstructed survival data from the phase III trial. 912 (67.1%) patients were classified as TOPAZ‐1‐in , and 446 (32.9%) as TOPAZ‐1‐out . After a median follow‐up of 14.5 months (95% CI: 13.7–36.5), OS was 16.1 months in TOPAZ‐1‐in and 12.5 months in TOPAZ‐1‐out (HR 0.69, 95% CI: 14.6–16.5, p = 0.0001); PFS was 8.2 versus 6.5 months (HR 0.73, 95% CI: 7.1–8.1, p < 0.0001). Median OS in the TOPAZ‐1‐out cohort (12.5 months) was nearly identical to the phase III trial experimental arm (12.9 months; HR 1.15, p = 0.13); for PFS the HR was 1.12 (95% CI 0.93–1.42; p = 0.09). Among TOPAZ‐1‐out patients, active infection, elevated bilirubin, and ECOG PS > 1 were linked to poorer OS, while no detrimental impact emerged for ALT/AST abnormalities, corticosteroid use, renal or hematologic parameters, or prior surgery within 6 months, suggesting treatment effectiveness was broadly maintained across clinical subgroups. Furthermore, TOPAZ‐1‐out patients experienced no significant increase in adverse events compared with the TOPAZ‐1‐in group. Real‐world data suggest CGD may be effective in TOPAZ‐1‐out patients, with no evident increase in toxicity, supporting the potential expanded use of the regimen in clinical practice.
TNK1 is a targetable JAK-independent driver of STAT signaling and inflammation
Scott, Samuel, Vaughan, Alec , Egbert, Christina M., Chan, Tsz‐Yin, Bustos, Yaphet , Ashworth, Spencer, Truman, Jacob M., Moreno, Angela Per, Tsang, Tsz‐Ming, Jayatunge, Dasun N., Yang, Jingshu, Nelson, Paige, Al-Sudani, Fatima, Tarara, Madelyn, Kohler, Emmalee, Mendiola, Nelson E. Pereira, Soderblom, Erik J. , Kolasangiani, Reza , Dobish, Kasidy K., Knobel, Beate, Buckley, Shannon M., Bidone, Tamara C., Morawe, Mareen , Armacki, Milena , Andersen, Joshua L., Stewart, Paul A , Smoot, Rory L , López-Palacios, Tania P. , Madhusanka, Deshan , Scott, Samuel M., Egbert, Christina M. , Truman, Jacob, Jayatunge, Dasun , Nelson, Paige, Stubben, Chris , Buckley, Shannon M. , Bidone, Tamara C. , Smoot, Rory L. , Uchida, Amiko M. , Andersen, Joshua L.

Mayo Clinic

Genes & Development | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353368.125 | PMID 42547268 Get It

Deregulated inflammatory signaling via STAT family transcription factors, particularly STAT1, underlies a variety of immune-related diseases, including inflammatory bowel disease. Whereas activation of STATs by JAKs via canonical receptor-driven JAK–STAT signaling is well understood, little is known about JAK-independent mechanisms of STAT activation. Here, we identify the understudied nonreceptor tyrosine kinase TNK1 as a therapeutically targetable, JAK-independent activator of STAT signaling. Using a multiomics approach, we mapped a network of TNK1 substrates associated with protein condensates and proinflammatory signaling, including STAT1. We found that TNK1, but not its sister kinase ACK1, directly phosphorylates STATs at well described STAT-activating JAK sites. In cells, TNK1-mediated STAT1 phosphorylation and activation occurs independently of JAKs. Imaging and interactomics data suggest that TNK1 interacts with STAT1 in cytosolic condensates, which likely compartmentalize TNK1-substrate interactions. We show that an intrinsically disordered proline-rich region in TNK1, which includes a 14-3-3 docking phosphorylation site, is required for the formation of kinase-active TNK1 condensates and STAT1 phosphorylation. Mutations within the proline-rich region that eliminate 14-3-3 binding increase formation of TNK1 condensates, suggesting a model in which 14-3-3 acts as a clamp that constrains the flexible PRR to inhibit condensate formation and STAT1 activation. Finally, we show that TNK1 is a targetable driver of STAT1-mediated inflammation in the gut as inhibition of TNK1 reduces active STAT1 in the colon and ameliorates colitis symptoms in mice.
Convalescent Plasma Restores Viral Clearance After Anti‐Spike Monoclonal Antibody Failure in Immunocompromised COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Individual Patient Data
Focosi, Daniele , Aiello, Tommaso Francesco , Cruciani, Mario , D’Abramo, Alessandra , Marco, Patrizia De, Garcia‐Vidal, Carolina, Glingani, Claudia, Hueso, Thomas , Richier, Quentin , Tomisti, Luca , Weinbergerova, Barbora, Zani, Matteo , Zaremba, Solomiia , Cruciani, Mario , D'Abramo, Alessandra , De Marco, Patrizia , Gachoud, David , Hueso, Thomas , Joyner, Michael J , Lacombe, Karine , Mengoli, Carlo , Nicastri, Emanuele , Richier, Quentin , Rufer, Nathalie , Senefeld, Jonathon W , Sullivan, David J , Zaremba, Solomiia , Franchini, Massimo , Focosi, Daniele , Casadevall, Arturo , García‐Vidal, Carolina , Joyner, Michael J. , Mengoli, Carlo , Senefeld, Jonathon W. , Shoham, Shmuel , Sullivan, David , Weinbergerová, Barbora , Franchini, Massimo

Mayo Clinic

Reviews in Medical Virology | July 31, 2026 | Volume: 36 | Issue: 5 | Pages: No page available

10.1002/rmv.70185 | PMID 42536824 Get It

ABSTRACT Anti‐Spike monoclonal antibodies (mAbs) progressively lost efficacy during the COVID‐19 pandemic due to the emergence and predominance of resistant SARS‐CoV‐2 variants. By contrast, high‐titre COVID‐19 convalescent plasma (CCP) collected from vaccinated donors recently recovered from infection provides a polyclonal source of antibodies that remains effective in clearing SARS‐CoV‐2 in immunosuppressed patients, unable to mount an adequate immune response against the virus. We conducted a systematic review and individual participant data meta‐analysis to examine the effect of CCP in immunocompromised patients persistently positive for SARS‐CoV‐2 viraemia following mAb therapy, and to evaluate possible biological factors associated with a favourable outcome. Electronic databases were searched for studies published from January 2020 to January 2026. All studies including eligible cases were considered in the systematic review. Unpublished cases were also collected from investigators of the selected studies. The protocol was registered at PROSPERO (CRD420251142891). Forty‐seven cases (30 cases from 12 published studies and 17 unpublished cases) were included. In 33 out of 47 patients (70.2%) with a mAb‐resistant infection, SARS‐CoV‐2 clearance occurred following CCP transfusion, with a mean of 2.7 CCP units administered. In logistic regression, total CCP volume transfused was positively associated with SARS‐CoV‐2 clearance. In conclusion, CCP transfusion was associated with SARS‐CoV‐2 clearance in persistently positive immunocompromised patients following failure of anti‐Spike mAb therapy.
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Rimini, Margherita , Lamarca, Angela, Ikeda, Masafumi, Kim, Jin Won , Vogel, Arndt, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Martirena, A. , Perkhofer, Lukas , Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Bolnykh, Iakov, Lancianese, Alessia , Satake, Tomoyuki, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Viola, Massimo, Persano, Mara , Balsano, Rita , Ratti, Francesca, Rimassa, Lorenza , Kim, Jin Won , Vivaldi, Caterina , Formica, Vincenzo , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Lamarca, Angela , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Vogel, Arndt , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno , Chon, Hong Jae , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Ferrara, Michele , Kang, Minsu, Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Ratti, Francesca , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70641 | PMID 42524843 Get It

ABSTRACT Surgery after response to first‐line chemoimmunotherapy may offer a potential curative option for patients with locally advanced biliary tract cancer (BTC) initially considered unresectable. However, robust real‐world evidence in this setting remains limited. We retrospectively analyzed patients with locally advanced BTC treated with first‐line cisplatin, gemcitabine, and durvalumab (CGD) across 55 centers in 12 countries. Endpoints included overall survival (OS), progression‐free survival (PFS), disease‐free survival (DFS) among resected patients, objective response rate (ORR), and the prognostic impact of surgery. A multivariable logistic regression model was developed to predict surgical conversion using baseline clinical and laboratory variables. Among 1358 screened patients, 219 had locally advanced disease and were included in the analysis. Median follow‐up was 14.5 months. ORR was 34.6%, with median PFS and OS of 10.0 and 20.7 months, respectively. Twenty‐four patients (10.9%) underwent surgical resection after systemic therapy. Median OS was 22.5 months in resected patients versus 19.9 months in those who did not undergo surgery. Median DFS after resection was 15.8 months. Pathological lymph node involvement was independently associated with shorter DFS. Larger baseline tumor size correlated with higher odds of radiological response but not with OS. An exploratory elastic‐net model retained four baseline variables and showed moderate discriminative ability for surgical conversion, with an apparent AUC of 0.72 and an optimism‐corrected AUC of 0.65. First‐line CGD enabled secondary resection in approximately 11% of patients with locally advanced BTC. A simple baseline model may support patient selection for conversion surgery, although prospective validation is needed.
Factors associated with aortic valve calcification in type 2 diabetes—a Steno INTEN-CT substudy
Haujir, Amal , Kumarathurai, Preman , Stidsen, Jacob V. , Funck, Kristian Løkke , Mohammad, Batool J Y, Ravn, Emil Johannes , Engelsgaard, Camilla, Ramanathan, Ramshanker , Madsen, Lene Helleskov, Hansen, Monija Mrgan, Böttcher, Morten, Pietraszek, Anna , Olsen, M, Karon, Marek , Hansen, Tine W. , Eskesen, Kristian , Calderon, Elena , Lambrechtsen, Jess , Øvrehus, Kristian Altern , Diederichsen, Axel CP, Dahl, Jordi S, Diederichsen, Axel Cosmus Pyndt , Funck, Kristian Løkke , Ravn, Emil Johannes , Kofoed, Klaus Fuglsang , Karon, Marek , Lambrechtsen, Jess , Clavel, Marie-Annick , Diederichsen, Axel , Haujir, Amal , Poulsen, Per Løgstrup , Mohammad, Batool J.Y., Hasific, Selma , Engelsgaard, Camilla Skals , Bøttcher, Morten , Olsen, Michael Hecht , Clavel, Marie‐Annick , Dahl, Jordi S.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjci/jeag139 | PMID 42290203 Get It

Abstract Aims This study aimed to identify clinical factors associated with AVC in individuals with T2D. Methods and results This cross-sectional study is a pre-specified substudy of the multicentre randomized Steno INTEN-CT trial (Clinical Trials—INTEN-CT). Participants were eligible if they had T2D without ischaemic heart disease and were aged between 55–69 years (men) or 60–74 years (women). All participants underwent non-contrast cardiac computed tomography. AVC was measured in Agatston Units and categorized as 0, 0–300, ≥ 300. Of the 4570 participants, 46% had AVC &gt; 0. With increasing AVC, patients were older, predominantly males, and with significantly more comorbidities. In multivariable ordered logistic regression age (OR per SD 1.54, 95% CI 1.43–1.66), BMI (OR per SD 1.18, 95% CI 1.11–1.25), hypertension (OR 1.21, 95% CI 1.05–1.40), and chronic kidney disease (OR 1.18, 95% CI 1.03–1.36) were associated with higher AVC. Statin use was also associated with higher AVC (OR 1.50, 95% CI 1.27–1.78). Higher LDL cholesterol showed stronger associations with AVC in men than women (OR 1.39, 95% CI 1.24–1.56 vs. OR 1.16, 95% CI 1.02–1.31, P for interaction = 0.025). T2D severity (Haemoglobin A1c, T2D duration, and number of antidiabetic drugs) was not associated with AVC. Conclusion In individuals with T2D without cardiovascular disease, AVC is prevalent in nearly half of all individuals. Higher AVC was associated with T2D-related comorbidities, but not T2D severity.
Incidence and Outcomes of Refractory Septic Shock per Consensus Clinical Criteria: A Multicohort Retrospective Study
Bauer, Seth R. , Wieruszewski, P M, Khanna, Ashish K., Leone, Marc, Barreto, E, DUGAR, SIDDHARTH, Mourany, Lyla, Reddy, Anita J, Tarabichi, Yasir, Wang, X, Vachharajani, Vidula, Bauer, Seth R , Wieruszewski, Patrick M. , Khanna, Ashish K. , Léone, Marc , Frazee, Erin N. , Dugar, Siddharth , Sacha, Gretchen , Mourany, Lyla, Gunsalus, Paul R. , Milinovich, Alex , Kane‐Gill, Sandra L. , Tarabichi, Yasir , Dalton, Jarrod E. , Vachharajani, Vidula

Mayo Clinic

Critical Care Medicine | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ccm.0000000000007234 | PMID 42240423 Get It

Objectives: Consensus clinical criteria for refractory septic shock were recently developed, but the incidence and outcomes with these criteria are unknown. There were two aims: 1) to describe the incidence of refractory septic shock and 2) to assess outcomes of patients with septic shock meeting refractory septic shock criteria compared with those who did not. Design: Multicohort, retrospective study. For aim 1, a descriptive epidemiologic study was designed to ascertain the cumulative incidence of refractory septic shock in patients with septic shock. For aim 2, a cohort study was conducted to compare hospital mortality between patients meeting refractory septic shock clinical criteria compared with those who did not. Setting: Large U.S. health system from 2012 to 2024. Patients: Adults (age ≥ 18 yr) meeting both Centers for Disease Control and Prevention Adult Sepsis Event and Sepsis-3 clinical criteria for septic shock. Patients with missing hospital discharge disposition and incomplete vasopressor dosage information were excluded. Interventions: None. Measurements and Main Results: Clinical criteria for refractory septic shock were operationalized as concomitant occurrence of norepinephrine (base) equivalent greater than 0.5 µg/kg/min and lactate greater than 2 mmol/L. Risk-adjusted hospital mortality was assessed with a generalized linear mixed-effects model with a random effect for hospital and fixed effects for age, sex, Elixhauser Comorbidity Index, and Sequential Organ Failure Assessment (original description, without cardiovascular component). Of 35,914 patients assessed, 15,732 patients with septic shock were included. Refractory septic shock occurred in 3423 patients (21.8%), with a cumulative incidence of 218 cases (95% CI, 211–224) per 1000 patients with septic shock. Hospital mortality with refractory septic shock was 64.4%, and risk-adjusted hospital mortality odds were 4.87-fold higher (95% CI, 4.46–5.31) compared with patients without refractory septic shock. Conclusions: Clinical criteria for refractory septic shock were fulfilled in about one in five patients with septic shock and associated with substantially higher mortality.
A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.
Ailawadhi, Sikander, Musuraca, Gerardo, Jurczak, Wojciech, Gutierrez, Antonio, Иванов, В В , Misyurina, Elena, Наилевна, Хусаинова Гульнара, Tumyan, Gayane, Visentin, Andrea, Tani, Monica , Tomuleasa, Ciprian, Mikuskova, Eva, Yang, Dajun, Zhai, Yifan, Davids, Matthew S. , Ailawadhi, Sikander , Musuraca, Gerardo , Jurczak, Wojciech , Šimkovič, Martin , Malek, Sami N. , Nikitin, Eugene A. , Misyurina, Elena N , Khusainova, Gulnara N. , Tumyan, Gayane Sergeevna , Tomowiak, Cécile , Dû, Katell Le , Visentin, Andrea , Tomuleasa, Ciprian , Yang, Dajun, Zhai, Yifan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps7101 Get It

TPS7101 Background: Patients with high-risk CLL/SLL not achieving a complete response (CR) after ≥ 12 months of BTK inhibitor (BTKi) monotherapy remain at risk for early progression due to residual disease and BTKi resistance. A BCL-2 inhibitor (BCL-2i) introduces a complementary, BCR-independent apoptotic mechanism that may deepen responses and prolong progression-free survival (PFS). Lisaftoclax, a selective oral BCL-2i with a short half-life (4-6 h), enables once-daily dosing and is approved in China as second-line CLL therapy. Lisaftoclax monotherapy has demonstrated overall response rates (ORRs) of 67% in relapsed/refractory CLL and 62.5% in BTKi-refractory disease, including del(17p)/ TP53 -mutated cases. Lisaftoclax combined with acalabrutinib achieved ORRs >97% with favorable tolerability. This study evaluates whether lisaftoclax plus BTKi (acalabrutinib, zanubrutinib, or ibrutinib) improves PFS and/or overall survival (OS) (vs continued BTKi monotherapy) in patients with CLL/SLL and residual disease after prolonged BTKi treatment. Methods: This study will enroll approximately 440 patients randomly allocated to receive lisaftoclax plus BTKi or BTKi alone. Eligible patients have CLL/SLL and, after ≥12 months of BTKi monotherapy (lines 1-3), have achieved neither CR nor progressive disease (PD). Randomization is stratified by del(17p)/ TP53 status. Key inclusion criteria include age ≥18 years, ECOG PS 0-2, and residual disease with either high-risk features (del(17p)/ TP53 mutation, unmutated IGHV , or complex karyotype [≥5 abnormalities]), or measurable residual disease with lymph nodes ≥2.5 cm in the absence of high-risk features. Exclusion criteria include prior BCL-2i therapy or Richter transformation. Patients in the investigational arm will undergo a 5-day oral lisaftoclax ramp-up to 400 mg once daily plus physician's choice of BTKi in 28-day cycles until progression or toxicity. Control patients continue their current BTKi monotherapy. Safety and disease assessments (CT/MRI) will occur regularly. The primary endpoint is PFS by independent review committee (iwCLL 2018); key secondary endpoint OS; and other secondary endpoints, PFS by investigator, ORR, duration of response, MRD negativity, and safety. Enrollment is ongoing across 126 sites in 18 countries (ClinicalTrials.gov ID: NCT06104566). Clinical trial information: NCT06104566 .